SWIM climbed roughly 37.7% over the last 30 days, rising from a close near $6.00 on October 14 to $8.26 by November 13. The advance was powered by strong third-quarter 2026 results and a narrowed, higher full-year outlook from management.
WMS rose from $123.51 at the prior close to $125.46 in early regular-session trading on Nov 13, a gain of +1.58% (+$1.95), as of the latest quote. No verified news or fundamental catalyst found; the move is likely a rebound after the prior session's -4.48% slide toward the 52-week low of $119.53, consistent with a stock whose typical daily move is about 1.8%.
MAS has posted stronger recent momentum, beating third-quarter earnings estimates and raising full-year guidance, while FBIN has been working through execution issues and portfolio restructuring. The two companies overlap in the residential building-products market but diverge sharply in profitability trajectory and near-term growth drivers.
The central target discussed here is $1.00 , roughly 56% above a recent price near $0.64. It is not an analyst consensus; it reflects a publicly referenced "Hold" rating with a $1.00 objective and the psychological $1.00 round-number level the stock briefly approached in late October 2026. OLOX has essentially no institutional sell-side coverage. TipRanks lists zero covering analysts, and MarketBeat reports a single sell rating with no consensus price target, so no reliable average analyst price target can be calculated.
This analysis examines whether Bio Green Med Solution, Inc. (BGMS) can climb to a $1.00 price objective, roughly 39% above its recent price near $0.72. Because BGMS has essentially no active, credible sell-side coverage, the $1.00 target comes from public discussion and technical context, not an analyst consensus.
The central $9.00 target is the arithmetic mean of eight verifiable analyst price targets, which range from $7.00 to $12.00. With AIRJ trading near $2.30, reaching $9 would require roughly 290% upside — a very large move for a 12-month horizon.
AirJoule Technologies (AIRJ) is expected to report third quarter 2026 results before the market opens on Monday, November 16, 2026. Analyst consensus points to a net loss of roughly $0.08 per share (EPS, earnings per share), alongside modest early revenue of approximately $100,000 as commercialization begins.
The central target examined here is $4 , reflecting a single published analyst price target rather than a broad consensus. The latest verified price is about $1.28 , meaning the stock would need to rise roughly 212% to reach the target.
The central stock price target of $7.30 is the arithmetic mean of the two most clearly attributable, current analyst price targets reviewed: KeyBanc's $9.00 and UBS's $5.60. With shares trading near $3.90 after the November 10, 2026 report, reaching $7.30 would require roughly an 87% gain — a very large move.
Janus International Group (NYSE: JBI) reported third quarter fiscal 2026 revenue of $213.1 million , down 2.8% from $219.3 million a year earlier. The company swung to a net loss of $13.3 million , or $0.10 per diluted share, versus net income of $15.2 million ($0.11 per share) in the prior-year quarter.
Carlisle Companies (CSL) slipped -0.94% during regular market hours, easing from a $396.61 prior close to roughly $392.88 by late morning. No verified news or fundamental catalyst found. The move likely reflects routine profit-taking after a sharp run—shares gained +7.6% on the Oct 29 Q3 earnings reaction and +5.6% on Nov 9—with today's -0.94% swing well inside the stock's typical ~1.8% daily range.
Griffon (GFF) slipped -1.43% during regular market hours, easing from a prior close of $106.77 to about $105.24. No verified news or fundamental catalyst found. The decline is likely profit-taking after the prior session's +5.68% surge, with no company-specific announcements published before the move.
The central target of $120 is the rounded arithmetic mean of three verified analyst price targets, not a published consensus. Griffon Corporation (GFF) recently traded near $106.77, so reaching $120 would require a rise of roughly 12%.
AAON jumped from its previous close of $62.87 to $77.54, up +23.33%, during Tuesday's regular session after gapping higher in premarket. The cause was Q3 results released after Monday's close: adjusted EPS of $0.83 crushed the ~$0.57 consensus and revenue rose +84% to $707.4M, with full-year sales-growth guidance raised to 72%–75% from 55%–60%.
Janus International (JBI) fell to $3.95 from a prior close of $4.76, a -17.02% move, during regular market hours after gapping down in premarket. The drop followed Q3 2026 results reported before the open: adjusted EPS of $0.08 missed the $0.18 consensus, and revenue of $213.1M missed the roughly $235M estimate.
INVE Technologies (formerly Identiv) is expected to report its third-quarter 2026 results — the quarter ended September 30, 2026 — with the full report scheduled for around November 9–12, 2026. The company has already issued revised preliminary figures: a net loss of $1.1 million to $1.3 million, or $0.05 to $0.06 per share, driven by post-closing adjustments tied to its asset sale to Trackonomy Systems.
The central target of $3.40 is the arithmetic mean of three verified, current analyst price targets, which range from $3.10 to $4.00 . The latest verified price of roughly $2.66 implies a required upside of about 28% to reach the $3.40 target — a substantial move for a stock of this size.
The central target used here is $120 , the arithmetic mean of the three most recent, individually verifiable analyst price targets: Oppenheimer's $115 (October 2026), D.A. Davidson's $110 (September 2026), and Robert W. Baird's $135 (August 2026). The stock closed near $62.87 on November 9, 2026, before surging in after-hours trading to roughly $72 following its third-quarter report, putting the target roughly 90% above the closing price.
A transformative reverse merger is the central catalyst: Bio Green Med Solution has agreed to an all-stock business combination (a share exchange) with Malaysia-based Future NRG Sdn. Bhd., a renewable-energy and scheduled-medical-waste-treatment specialist, in a transaction valued at $2.0 billion. The deal is expected to close in the fourth quarter of 2026. Ownership structure will shift dramatically: If completed, Future NRG's selling shareholders are expected to hold more than 99% of the combined company, while pre-deal BGMS stockholders would hold less than 1% — making this effectively a reverse merger into a new operating business.
The central target of $1.00 is a fallback figure drawn from public discussion and valuation anchors, not an analyst consensus, because BGMS lacks a credible, current set of analyst price targets. Bio Green Med Solution, Inc. (NASDAQ: BGMS), formerly Cyclacel Pharmaceuticals, is a Malaysia-based micro-cap focused on fire-safety distribution with a market value of roughly $5.7 million.